Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Picard Medical, Inc. due to allegations of securities law violations, including misleading statements and undisclosed fraudulent activities [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Picard Medical between September 2, 2025, and October 31, 2025, to discuss their legal options [1]. - There is a deadline of April 13, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Picard Medical [2]. - The complaint alleges that Picard Medical and its executives made false statements and failed to disclose involvement in a fraudulent stock promotion scheme [4]. Group 2: Stock Performance and Impact - On October 24, 2025, Picard Medical's shares closed at $5.31, a significant drop from $13.20 on October 23, 2025, representing a decline of $7.89 per share or approximately 59.8% in a single trading session [5]. - This decline marks one of the most significant one-day drops since the company's recent IPO [5]. Group 3: Firm Background and Support - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in New York, Pennsylvania, California, and Georgia [3]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Picard Medical's conduct [7].

Core Insights - The New York Times Company reported better-than-expected earnings for Q4 2025, with earnings per share at $0.89 and revenue at $802.3 million, but the stock price fell significantly post-announcement, dropping 9.32% in pre-market trading and closing down 6.34% at $67.63 [2] Financial Performance - Q4 2025 results showed a revenue of $802.3 million and earnings per share of $0.89, exceeding market expectations [2] - Following the earnings report, trading volume surged to $614 million, a 70.67% increase from the previous day, with 9.4291 million shares traded, indicating heightened market interest [2] Strategic Outlook - For 2026, management anticipates continued growth in subscription users, revenue, and adjusted operating profit, with a revenue target of $3 billion and an expected earnings per share of $2.65 [3] - The company is focusing on expanding its video news business and increasing product development investments to adapt to competition in digital media and changing consumer habits [3] Industry Environment - Competitor dynamics reveal that The Washington Post announced a layoff of approximately 30% of its workforce and the closure of its sports department, highlighting the profitability pressures and technological disruptions faced by traditional media [4] - Legal and policy risks include ongoing legal disputes with the U.S. government, which may impact the company's news gathering capabilities and operational costs [4] Future Developments - The first quarter 2026 earnings report is expected in early April, with investors advised to monitor subscription growth and cost control progress [5] - Long-term challenges include tracking the momentum of digital subscription growth (with a net increase of 1.4 million users in 2025), the impact of economic uncertainty on advertising revenue, and the effects of AI technology on content distribution models [5]

Peter Baker is New York Times Chief White Hous Correspondent and an MSNOW contributor. Brendan Ballew is a former federal prosecutor, former attorney with the DOJ's national security division. MSNOW senior legal reporter Lisa Rubin is with me in studio.At one point, Pam Bondi pivoted from talking about Epstein to saying that the Dow was over 50 ,000 and, quote, we should be, that's what we should be talking about. She did not want to talk about Jeffrey Epstein, but I did think that Tom Massey was particular ...

Today, Donald Trump's prosecutors, who have found nothing to pursue in the Epstein files, tried and failed to get indictments against six Democratic members of Congress for saying this. You can refuse illegal orders. You can refuse illegal orders. You must refuse illegal orders.No one has to carry out orders that violate the law or our Constitution. We know this is hard. And that it's a difficult time to be a public servant.But whether you're serving in the CIA, the Army, our Navy, the Air Force, your vigil ...

Core Insights - The New York Times is adopting a voluntary incentive approach to password sharing, contrasting with Netflix's strict blocking method [1][2] - The introduction of the "Family Plan" aims to enhance subscriber engagement and retention while generating additional revenue [3] Strategy and Revenue Model - The Family Plan allows subscribers to include others under a premium-priced model, promoting a positive perception of subscriptions [2] - This model treats password sharing as a retention tool rather than a revenue loss, with the Family Plan expected to contribute positively to revenue from the outset [3] Financial Performance - The New York Times reported total digital revenues exceeding $2 billion for the first time in 2025, with a net addition of 450,000 digital subscribers in Q4, bringing the total to 12.8 million [4] - Year-to-date, NYT shares have increased by 1.29%, outperforming the S&P 500's 1.22% increase, with a 22.76% rise over the last six months and a 42.70% increase over the past year [5] Stock Performance - On a recent trading day, NYT shares closed 3% higher at $70.72, with a mixed short-term price trend but stronger long and medium-term trends according to Benzinga Edge's Stock Rankings [6]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Picard Medical, Inc. due to allegations of securities law violations, encouraging affected investors to seek legal counsel and participate in a class action lawsuit [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is urging investors who suffered losses in Picard Medical between September 2, 2025, and October 31, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Picard Medical, with a deadline of April 3, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Picard Medical and its executives made false or misleading statements and failed to disclose critical information regarding a fraudulent stock promotion scheme [4]. Group 2: Stock Performance and Impact - On October 24, 2025, Picard Medical's shares closed at $5.31, a significant drop from $13.20 on October 23, 2025, representing a decline of $7.89 per share or approximately 59.8% in a single trading session [5].

Ben Smith, your latest piece for Semaphore is titled How Trump's Politics Returned to EARTH AND IN IT YOU WRITE IN PART, TRUMP'S POLITICAL STANDING WHICH HAS EVOLVED OVER JUST A FEW MONTHS FROM DOMINANT TO DESPERATE IS A GOOD REMINDER OF A FEW THINGS CONVENTIONAL WISDOM HAS GOTTEN WRONG. REMEMBER THE DEEP FAKE, PANIC. LAST YEAR MANY WERE CONVINCED AMERICAN POLITICS WOULD BE DESTABILIZED BY VIDEOS MANIPULATED BY ARTIFICIAL INTELLIGENCE OR LULLED INTO A POST-TRUTH STUPOR BY AI SLOP.BUT IT TURNS OUT THAT THE P ...

[MUSIC] [FOREIGN] >> It was awesome. Even if you didn't understand a word of it, it made you smile, it made you dance. Hi again, everybody.It's five o'clock now in New York. What an uplifting end to a really amazing performance. You heard Bad Bunny there, God Bless America, he said, during his Super Bowl halftime show.Behind him on the Jumbo Tron, you couldn't miss it. It said, the only thing more powerful than hate is love. And on the football he was carrying, together we are America.Inspiring, positive, d ...

But we begin tonight with a tr of federal agencies all facing self-inflicted political crisis. Breaking tonight, MSNOW confirms Director of National Intelligence, Tulsi Gabbard, will appear before the Senate Intelligence Committee on March 18th. That's according to a source familiar with the matter.That comes as we learn new details about that top secret whistleblower complaint, Gabbard attempted to shield from key parties. According to the New York Times, the complaint involved an intelligence intercept of ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Picard Medical, Inc. due to allegations of securities law violations, encouraging affected investors to come forward [2][4]. Group 1: Legal Investigation - The law firm is urging investors who suffered losses exceeding $50,000 from purchasing Picard Medical securities between September 2, 2025, and October 31, 2025, to contact them for legal options [1]. - A federal securities class action has been filed against Picard Medical, with a deadline of April 3, 2026, for investors to seek the role of lead plaintiff [2][5]. Group 2: Allegations Against Picard Medical - The complaint alleges that Picard Medical and its executives made false and misleading statements, failing to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [4]. - It is claimed that insiders and affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign, and that the company's public statements omitted critical information regarding false rumors and artificial trading activity affecting stock prices [4]. Group 3: Firm Background - Faruqi & Faruqi, LLP is a prominent national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].